Vanda Pharmaceuticals Inc. (VNDA) Stock Price & Analysis
Vanda Pharmaceuticals Inc. (VNDA) fell 3.36% to USD 5.18 as of July 25, 2026 at 06:51 UTC, according to Nexqual real-time market data.
VNDA last closed at USD 5.36; the session ranged USD 5.12–5.39 on volume of 758,391 shares. Market capitalization is $311.50M, with a 52-week range of USD 4.14–9.94 (NGM). Source: Nexqual, July 25, 2026 at 06:51 UTC.
Key Statistics (as of July 25, 2026 at 06:51 UTC)
| Price | USD 5.18 |
|---|---|
| Change | ▼ 3.36% (down) |
| Previous Close | USD 5.36 |
| Open | USD 5.39 |
| Day Range | USD 5.12 – 5.39 |
| 52-Week Range | USD 4.14 – 9.94 |
| Volume | 758,391 shares |
| Market Cap | $311.50M |
| Exchange | NGM |
Technical Analysis (VNDA)
Nexqual's technical model rates VNDA "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:51 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.71 (neutral) |
| vs SMA50 | Below (USD 6.02) |
| MACD | -0.23 (negative) |
Analyst Ratings (VNDA)
Wall Street analysts rate VNDA "Strong Buy" based on 4 analysts, with a mean price target of USD 14.13 (range USD 7.5–21), per Nexqual as of July 25, 2026 at 06:51 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 14.13 |
| High Target | USD 21 |
| Low Target | USD 7.5 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (VNDA)
| Next Earnings Date | 2026-07-29 |
|---|---|
| Revenue Estimate | $61.92M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.82 vs est -0.69 ▼ miss |
| 2025-12-31 | USD -2.39 vs est -1.33 ▼ miss |
| 2025-09-30 | USD -0.38 vs est -0.45 ▲ beat |
| 2025-06-30 | USD -0.46 vs est -0.36 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:51 UTC.
Financials & Fundamentals (VNDA)
| Total Revenue | $217.78M |
|---|---|
| Revenue Growth (YoY) | +3.40% |
| Gross Margin | +94.18% |
| Operating Margin | -97.11% |
| Profit Margin | -109.99% |
| ROE | -60.48% |
| Debt / Equity | 4.66 |
| Current Ratio | 2.16 |
| Total Cash | $202.31M |
| Total Debt | $13.07M |
| Free Cash Flow | $-83.15M |
Source: Nexqual, July 25, 2026 at 06:51 UTC.
Financial Health Score (VNDA)
Nexqual rates Vanda Pharmaceuticals Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 06:51 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 94%, operating -97% |
| Balance Sheet | Strong — $202M cash vs $13M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$83M, burning cash |
| Efficiency | Critical — ROE -60%, ROA -18.8% |
Ownership (VNDA)
| Insider Ownership | +6.65% |
|---|---|
| Institutional Ownership | +78.81% |
| Shares Outstanding | 60.14M |
| Float | 53.84M |
| Short % of Float | +12.55% |
Source: Nexqual, July 25, 2026 at 06:51 UTC.
Leadership (VNDA)
Vanda Pharmaceuticals Inc. is led by Mihael H. Polymeropoulos (age 65), Founder, President, CEO & Chairman of The Board, per Nexqual as of July 25, 2026 at 06:51 UTC.
| Founder, President, CEO & Chairman of The Board | Mihael H. Polymeropoulos (age 65) |
|---|---|
| Senior VP, CFO & Treasurer | Kevin Patrick Moran (age 41) |
| Senior VP & Chief Marketing Officer | Joakim Wijkstrom (age 59) |
| Senior Vice President of Business Development | Gunther Birznieks (age 56) |
| Senior Vice President & Medical Director | Christos Polymeropoulos |
Major Backers & Investors (VNDA)
Notable institutional backers of Vanda Pharmaceuticals Inc. include Renaissance Technologies, AIGH Capital Management LLC, Millennium Management, according to Nexqual as of July 25, 2026 at 06:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 6.25% |
| AIGH Capital Management LLC | 4.57% |
| Millennium Management | 3.13% |
| Acadian Asset Management. LLC | 2.99% |
| AQR Capital Management, LLC | 2.67% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 16.66% |
| State Street | 8.81% |
| Vanguard Group | 8.17% |
| Dimensional Fund Advisors | 2.95% |
| Geode Capital | 2.4% |
Source: Nexqual, July 25, 2026 at 06:51 UTC.
From Vanda Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
- The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
- In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders.
- Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IRWD | Ironwood Pharmaceuticals, Inc. | USD 3.71 | ▼ 4.38% |
| SUPN | Supernus Pharmaceuticals, Inc. | USD 46.2 | ▼ 1.58% |
| CYTK | Cytokinetics, Incorporated | USD 80.74 | ▼ 1.76% |
| RIGL | Rigel Pharmaceuticals, Inc. | USD 36.74 | ▼ 2.8% |
| OMER | Omeros Corporation | USD 9.79 | ▼ 0.51% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:51 UTC. This page is informational and not investment advice.